PARKINSON’S
disease

Several movement alterations correlate with modifications to EEG activities.
In Parkinson’s disease, specific antikinetic and prokinetic oscillatory activities (beta and gamma) are prominent. These activities can therefore be used as surrogate translational biomarkers for Drug Discovery.

BetaPark
Strong Biomarker for Parkinson’s Disease

  • Pharmacosensitive
  • Expressed in PD patients
  • Incredibly stable over time
  • Objective, non tremor related
  • Exclusively revealed by Cue® and EEG​

Clinical observations describe a pathological activity in the 30Hz band (Beta) in parkinsonian patients (PD).
This Beta activity drops with movement initiation.
Part of our Movement disorders programs, the unilateral 6-OHDA lesioned rat is a well known model of Parkinson’s disease.
The specific Beta oscillation (BetaPark) is found in the 6-OHDA rat motor cortex as found in PD patients.

The BetaPark biomarker can be modulated by a pharmacology of reference (Dopamine agonists).
You can assess the pharmacodynamic effects of your compound on BetaPark and objectively evaluate how it compares to reference drugs.

Meet BetaPark
in 4 Steps